Strontium ranelate, an osteoporosis drug that simultaneously enhances osteoprotegerin (OPG) expression and downregulates RANKL expression in primary human osteoblastic cells, leading to decreased osteoclastogenesis and bone resorption, has been shown to ameliorate pain as well as cartilage volume loss and bone marrow lesions in OA patients [105,106,107]. The gene discussed is TNFRSF11B; the disease is osteoporosis.